In Vivo Effects of Immunomodulators in a Murine Model of Fluorouracil-Induced Mucositis

Current Therapeutic Research - Clinical and Experimental

Volumn 72, Issue 6, 2011, Pages 262-272

  Tung, David ^a   Cheung, Peter H ^a   Tudor, Gregory ^b   Booth, Catherine ^b   Saha, Saurabh ^a  

^a BioMed Valley Discoveries   (United States)

^b Epistem Ltd   (United Kingdom)

Author keywords

Cyclosporine; Etanercept; Fluorouracil; Mucositis

Indexed keywords

CYCLOSPORIN; ETANERCEPT; FLUOROURACIL; HEMATOXYLIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIARRHEA; IN VIVO STUDY; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL; WEIGHT REDUCTION;

EID: 83355177311     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2011.11.003     Document Type: Article

References (35)

1. Heidelberger C., Ansfield F.J. Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 1963, 23:1226-1243.
2. Ardalan B., Glazer R. An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev 1981, 8:157-167.
3. Letari O., Booth C., Bonazzi A., et al. Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol 2010, 66:819-827.
4. Smith C.L., Geier M.S., Yazbeck R., et al. Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr Cancer 2008, 60:757-767.
5. Whitford E.J., Cummins A.G., Butler R.N., et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 2009, 8:505-511.
6. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 2004, 20:11-15.
7. Logan R.M., Gibson R.J., Bowen J.M., et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008, 62:33-41.
8. Sonis S.T. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007, 5:3-11.
9. Franko A.J., Sharplin J., Ghahary A., Barcellos-Hoff M.H. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radiat Res 1997, 147:245-256.
10. Johnston C.J., Piedboeuf B., Rubin P., et al. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res 1996, 145:762-767.
11. Zhang M., Qian J., Xing X., et al. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 2008, 14:1868-1876.
12. Matsushima Y., Baba T. The in vivo effect of cyclosporine A on macrophages. J Exp Pathol 1990, 5:39-48.
13. Hess A.D., Esa A.H., Colombani P.M. Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988, 20:29-40.
14. Colombani P.M., Hess A.D. T-lymphocyte inhibition by cyclosporine. Potential mechanisms of action. Biochem Pharmacol 1987, 36:3789-3793.
15. Bunjes D., Hardt C., Rollinghoff M., Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981, 11:657-661.
16. Garcia J.E., Lopez A.M., de Cabo M.R., et al. Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. Mediators Inflamm 1999, 8:253-259.
17. Chiara M.D., Bedoya F., Sobrino F. Cyclosporin A inhibits phorbol ester-induced activation of superoxide production in resident mouse peritoneal macrophages. Biochem J 1989, 264:21-26.
18. Palay D.A., Cluff C.W., Wentworth P.A., Ziegler H.K. Cyclosporine inhibits macrophage-mediated antigen presentation. J Immunol 1986, 136:4348-4353.
19. Manca F., Fenoglio D., Kunkl A., et al. Effect of cyclosporine on the antigen-presenting function of human and murine accessory cells. Transplantation 1988, 46:40S-43S.
20. Manca F., Kunkl A., Celada F. Inhibition of the accessory function of murine macrophages in vitro by cyclosporine. Transplantation 1985, 39:644-649.
21. Drath D.B., Kahan B.D. Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation 1983, 35:588-592.
22. Whisler R.L., Lindsey J.A., Proctor K.V., et al. Characteristics of cyclosporine induction of increased prostaglandin levels from human peripheral blood monocytes. Transplantation 1984, 38:377-381.
23. Keefe D.M., Cummins A.G., Dale B.M., et al. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997, 92:385-389.
24. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000, 47:632-637.
25. Maj J.G., Paris F., Haimovitz-Friedman A., et al. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 2003, 63:4338-4341.
26. Hong J.H., Chiang C.S., Tsao C.Y., et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 1999, 75:1421-1427.
27. Xun C.Q., Thompson J.S., Jennings C.D., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994, 83:2360-2367.
28. Ong Z.Y., Gibson R.J., Bowen J.M., et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010, 5:22.
29. Logan R.M., Stringer A.M., Bowen J.M., et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007, 33:448-460.
30. Haagen J., Krohn H., Rollig S., et al. Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 2009, 92:472-476.
31. Huang X.W., Yang J., Dragovic A.F., et al. Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clin Cancer Res 2006, 12:2849-2855.
32. Losa Garcia J.E., Rodriguez F.M., Martin de Cabo M.R., et al. Evaluation of inflammatory cytokine secretion by human alveolar macrophages. Mediators Inflamm 1999, 8:43-51.
33. Tipton D.A., Pabst M.J., Dabbous M.K. Interleukin-1 beta- and tumor necrosis factor-alpha-independent monocyte stimulation of fibroblast collagenase activity. J Cell Biochem 1990, 44:253-264.
34. Rofe A.M., Philcox J.C., Haynes D.R., et al. Changes in plasma zinc, copper, iron, and hepatic metallothionein in adjuvant-induced arthritis treated with cyclosporin. Biol Trace Elem Res 1992, 34:237-248.
35. Fox B.S., Sonis S. TNF and oral mucositis: response to effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 2009, 92:472-476.